Related Experiment Video
Updated: May 2, 2026

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs
Published on: December 24, 2015
Uremic toxins impair human bone marrow-derived mesenchymal stem cells functionality in vitro
Marta Idziak1, Piotr Pędzisz2, Anna Burdzińska1
1Department of Immunology, Transplantology and Internal Diseases, Transplantation Institute, Warsaw Medical University, Poland.
Abstract:
Mesenchymal stem cells (MSCs) are becoming therapeutic agents of interest in many areas of medicine, including renal diseases and kidney transplantations. However, the effect of uremia on cell properties is still unclear. Therefore, we examined the in vitro influence of uremic toxins, p-cresol (PC) and indoxyl sulfate (IS), on human bone marrow-derived MSC functionality. Cultured MSCs were treated with PC and IS at concentrations corresponding to subsequent stages of chronic kidney disease. Cell viability was characterized by metabolic activity (MTT assay) and proliferation rate (BrdU assay). Apoptosis (Annexin V test) and cell membrane damage (LDH assay) were also tested. MSC secretory properties were determined by measuring cytokine/growth factor levels in media from toxin-treated cells (ELISA). Uremic concentrations of PC and IS resulted in significant inhibition of MSC metabolic activity and proliferation. Toxins did not induce apoptosis, but damaged cell membranes. MSC paracrine activity was also altered - a decrease of VEGF and TGF-β1 levels and an increase in IGF-1 and IL-8 secretion was detected. Presented data indicate a negative influence of uremic toxins on functional characteristics of human bone marrow-derived MSCs. Therefore, their use as autologous therapeutic agents for kidney disease may be questionable and requires further investigations. The observed phenomenon may be attributable to many other MSC therapies, because of the high prevalence of chronic kidney disease in adult population.
Insights
Uremic toxins negatively impact mesenchymal stem cells (MSCs), reducing their viability and altering secretory functions. This challenges the use of MSCs as autologous therapies for kidney disease patients.
Area of Science:
- Cell Biology
- Nephrology
- Regenerative Medicine
Background:
- Mesenchymal stem cells (MSCs) show therapeutic promise for renal diseases.
- The impact of uremia on MSC functionality remains largely unknown.
- Uremic toxins, such as p-cresol (PC) and indoxyl sulfate (IS), accumulate in chronic kidney disease (CKD).
Purpose of the Study:
- To investigate the in vitro effects of uremic toxins (PC and IS) on human bone marrow-derived MSCs.
- To assess the influence of these toxins on MSC viability, proliferation, apoptosis, membrane integrity, and secretory properties.
Main Methods:
- MSCs were exposed to PC and IS at concentrations mimicking CKD stages.
- Cell viability assessed via MTT and BrdU assays.
- Apoptosis (Annexin V) and membrane damage (LDH) were measured.
- Secretory profiles analyzed by ELISA for cytokines and growth factors (VEGF, TGF-β1, IGF-1, IL-8).
Main Results:
- Uremic toxin concentrations significantly inhibited MSC metabolic activity and proliferation.
- Toxins did not induce apoptosis but caused cell membrane damage.
- MSC paracrine function was altered: decreased VEGF and TGF-β1, increased IGF-1 and IL-8 secretion.
Conclusions:
- Uremic toxins exert detrimental effects on human bone marrow-derived MSC functionality.
- The compromised function raises concerns about using autologous MSCs for kidney disease treatment.
- Further research is needed to validate MSC therapies in the context of uremia and CKD prevalence.
Related Concept Videos
Mesenchymal Stem Cells
Regulation of Hematopoietic Stem Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

